Kurma Partners — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
Synendos is a biotech company developing selective endocannabinoid reuptake inhibitors targeting the endocannabinoid system to treat neuropsychiatric disorders.
BiotechDeep TechDigital HealthMental HealthBasel, CH
Prof. Jürg Gertsch(Founder)Dr. Andrea Chicca(Co-Founder & Chief Executive Officer)Dr. Simon Russell(Co-Founder & Chief Commercial Officer)
Co-investorsYsios CapitalSunstone Capital
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.
BiotechHealthtech
Co-investorsAgent CapitalAndera PartnersPfizer Venture InvestmentsPureos BioventuresAlexandriaBpifrance+4 more
VICO provides AI-generated forecasts and event risk ratings that track and triangulate analyst views into continuous time series data.
AI & Machine LearningData & InfrastructureFintech
Co-investorsAIN VenturesMultiball CapitalDroia VenturesEQT Life SciencesEurazeoPureos Bioventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.